Literature DB >> 11597385

Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas.

H Huber1, A Eggert, A J Janss, R Wiewrodt, H Zhao, L N Sutton, L B Rorke, P C Phillips, M A Grotzer.   

Abstract

Primitive neuroectodermal brain tumours (PNET) including medulloblastomas (PNET/MB) are the most common malignant brain tumours of childhood. Similar to many other brain tumours, PNET/MB often show marked neovascularisation. To determine which angiogenic factors contribute to PNET/MB angiogenesis, we examined the expression of eight angiogenic factors (vascular endothelial growth factors (VEGF, VEGF-B, VEGF-C), basic fibroblast growth factor (bFGF), angiopoetins (Ang-1, Ang-2), transforming growth factor (TGF-alpha), and platelet-derived endothelial growth factor (PDGF-A)) by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in six PNET cell lines and 28 primary PNET/MB. Expression levels of angiogenic factors were compared with microvessel density, TrkC mRNA expression, clinical variables and survival outcomes. Our results indicate that all PNET/MB tested produce a wide range of angiogenic factors that are, individually or together, likely to play a direct role in PNET/MB tumour growth. This suggests that anti-angiogenesis approaches targeting VEGF alone may be insufficient in PNET/MB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11597385     DOI: 10.1016/s0959-8049(01)00225-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  24 in total

1.  Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.

Authors:  Sachiko Ohshima-Hosoyama; Monika A Davare; Suresh I Prajapati; Jinu Abraham; Sangeet Lal; Laura D Nelon; Aoife Kilcoyne; Francis J Giles; Martha A Hanes; Brian P Rubin; Charles Keller
Journal:  J Pediatr Hematol Oncol       Date:  2012-03       Impact factor: 1.289

Review 2.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

3.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Susan N Chi; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Henry S Friedman; Roger J Packer; Brian N Rood; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

4.  Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.

Authors:  Dolly Aguilera; Claire Mazewski; Jason Fangusaro; Tobey J MacDonald; Rene Y McNall-Knapp; Laura L Hayes; Sungjin Kim; Robert C Castellino
Journal:  Childs Nerv Syst       Date:  2013-01-08       Impact factor: 1.475

Review 5.  Anti-angiogenic therapy in pediatric neuro-oncology.

Authors:  Mark W Kieran
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

6.  Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.

Authors:  Tea Blom; Annariikka Roselli; Valtteri Häyry; Olli Tynninen; Kirmo Wartiovaara; Miikka Korja; Kristiina Nordfors; Hannu Haapasalo; Nina N Nupponen
Journal:  J Neurooncol       Date:  2009-09-25       Impact factor: 4.130

7.  Effects of basic fibroblastic growth factor on the growth of human medulloblastoma xenografts.

Authors:  Pascal Vachon; Christiane Girard; Yves Théorêt
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

8.  Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma.

Authors:  Robert C Castellino; Benjamin G Barwick; Matthew Schniederjan; Meghan C Buss; Oren Becher; Dolores Hambardzumyan; Tobey J Macdonald; Daniel J Brat; Donald L Durden
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

9.  Telomere maintenance in childhood primitive neuroectodermal brain tumors.

Authors:  Domenico Didiano; Tarek Shalaby; Doris Lang; Michael A Grotzer
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

10.  Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment.

Authors:  Yu Liang; Maximilian Diehn; Andrew W Bollen; Mark A Israel; Nalin Gupta
Journal:  J Neurooncol       Date:  2007-07-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.